Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%

Ruxolitinib vs best available therapy

Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF

Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with best available therapy (low certainty).

1 finding from 1 review

Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
RR 1.2 [0.44, 3.28]
1 study · 219 participants
Low

Ruxolitinib vs placebo

Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF

Ruxolitinib may leads to higher safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with placebo (low certainty).

1 finding from 1 review

Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
RR 9.74 [2.32, 40.96]
1 study · 306 participants
Low

Ruxolitinib vs placebo

Grade 3 to 4 neutropenia · Patients with treating MF

Ruxolitinib may leads to higher safety (AE, adverse drug reaction): neutropenia Grades 3 or 4… compared with placebo (low certainty).

1 finding from 1 review

Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
RR 3.57 [1.02, 12.55]
1 study · 306 participants
Low